Home / Clinical Guideline Hubs / Chapter 2.4
Section 2 — Care of the Preterm Infant Verify against local policy v1.0 · July 2026 Baylor Ed. 33 cross-checked Sept 2026

Chapter 2.4 — Apnea of Prematurity & Caffeine

Definition and types of apnea, the central role of caffeine, non-pharmacological measures, and the "apnea is a diagnosis of exclusion" rule — built on West Midlands Neonatal Guidelines 2025–28, the CAP trial, and AAP guidance

Educational guideline — verify locally. Caffeine dosing and monitoring must be verified against the Neonatal Formulary and local policy. New or worsening apnea is a red flag for underlying illness (sepsis, NEC, seizures) — investigate, don't just treat. Does not replace attending judgment.
BEDSIDE ACTION BOX

1. Overview

Overview

Apnea of prematurity (AOP) is a developmental disorder of respiratory control caused by an immature brainstem, with contributions from an immature response to CO₂ and hypoxia and from upper-airway instability. It is common below 34 weeks and typically resolves as the infant matures. The clinical priorities are to distinguish AOP from apnea caused by another illness, to treat effectively (caffeine plus supportive measures), and to time discharge safely.

Why This Topic Matters

Apnea can be the first sign of serious illness (sepsis, NEC, seizures), so treating it reflexively without evaluation is dangerous. Caffeine is one of the most beneficial NICU drugs — reducing apnea, BPD, and improving neurodevelopmental outcomes — and correct discharge timing prevents avoidable readmission and risk.

2. Who This Guideline Applies To

Scope
  • Preterm infants (especially <34 weeks) with apnea, and those receiving caffeine prophylaxis/treatment.
  • Any preterm infant with new or worsening apnea requiring evaluation.
  • Cross-references: VLBW care (2.1), RDS/respiratory support (6.1), sepsis (8.1/8.2), NEC (11.1), seizures (9.3), and anemia (10.2/10.5).

3. Key Definitions

TermDefinition
Apnea (significant)No breathing for 20 seconds or longer, or a shorter pause with bradycardia (<100/min), cyanosis or pallor.
Apnea of prematurityApnea due to immature respiratory control in a preterm infant, once other causes are excluded.
Periodic breathingCyclical breathing pauses without significant bradycardia/desaturation — usually benign.
BradycardiaHeart rate below the age-defined threshold (often <100/min), commonly accompanying apnea.

4. Types of Apnea

TypeMechanismNote
CentralNo respiratory effort (immature brainstem drive).Responds to caffeine.
ObstructiveEffort present but no airflow (airway collapse, neck flexion).Positioning/CPAP helps.
MixedCombination of central and obstructive (most common).Caffeine + CPAP/positioning.

5. Differential — Apnea Is a Diagnosis of Exclusion

Exclude Secondary Causes First
  • Infection: sepsis, meningitis, NEC — often the first sign.
  • Neurological: IVH, seizures, hypoxic-ischemic injury.
  • Respiratory: hypoxia, airway obstruction, worsening lung disease.
  • Metabolic: hypoglycemia, electrolyte disturbance, temperature instability (hypo/hyperthermia).
  • Haematological: anemia.
  • Other: GERD, drugs (maternal/neonatal sedatives), PDA, patent airway issues.

6. Caffeine — The Key Treatment

Benefits & Default Regimen (Baylor Ed. 33)
  • Caffeine citrate is first-line: it reduces apnea, facilitates extubation, reduces the need for ventilation, lowers BPD, and improves neurodevelopmental outcomes (CAP trial).
  • Dose: load 20 mg/kg, then 5 mg/kg once daily IV or enterally, increasing to a maximum of 10 mg/kg/day if apnea persists. Levels are not routinely checked.
  • Who: routinely for all infants <1250 g; above 28 weeks and off positive pressure it is reasonable to wait for apnea.
  • Stopping: trial off after 5–7 days free of significant apnea off positive pressure, or at 33–34 weeks PMA, whichever comes first; then monitor for 7 days (section 10+).
  • Well tolerated; watch for tachycardia, feed intolerance, and jitteriness at higher exposure.

Other sources: maintenance of 5–10 mg/kg/day from the outset is also used, and many formularies leave the stopping point to unit policy.

7. Non-Pharmacological Measures

Supportive Care
  • Optimal positioning (avoid neck flexion; prone positioning while monitored reduces obstructive events); thermoneutral environment.
  • CPAP or non-invasive support for obstructive/mixed apnea (splints the airway, improves oxygenation).
  • Treat anemia; ensure adequate oxygenation; manage GERD conservatively; minimize sedatives.
  • Gentle handling during feeds; monitor for apnea associated with feeding.

8. Management Algorithm

1
Acute episode
Tactile stimulation → PPV if no response; check airway, position, leads, and oxygenation.
2
New/worsening apnea? Evaluate
Exclude sepsis, NEC, IVH, seizures, anemia, hypoglycemia, temperature, GERD, drugs before attributing to prematurity.
3
Treat AOP
Start/continue caffeine; optimize positioning/thermal care; add CPAP for obstructive/mixed apnea; treat anemia.
4
Persistent/severe apnea
Re-evaluate for a secondary cause; escalate respiratory support; consider senior review.
5
Resolution & discharge planning
Stop caffeine after 5–7 apnea-free days off positive pressure or at 33–34 weeks PMA; monitor 7 more days before discharge.
6
⚠ Do-not-miss
Apnea as the herald of sepsis/NEC/seizures; obstructive apnea from malpositioning; and premature discharge before a safe apnea-free interval.

9. Monitoring

ParameterWhenAction
Apnea/bradycardia/desaturation eventsContinuousRecord type, frequency, severity, stimulation vs PPV.
Caffeine toleranceOngoingWatch tachycardia, feed intolerance, jitteriness.
Secondary-cause screenOn new/worsening apneaInvestigate and treat the cause.
Apnea-free intervalBefore discharge7 days free of spontaneous events after stopping caffeine.

10. Discharge Considerations

Safe Timing
  • Most preterm infants are stable by 36–37 weeks (very preterm infants may take until 43–44 weeks); discharge after 7 days of monitoring off caffeine, counting only spontaneous events (section 10+).
  • Ensure competent feeding, weight gain, and thermal stability; discuss safe sleep with parents.
  • Home monitoring is not routinely required; reserve for selected cases per specialist advice.

10+. Baylor Ed. 33 Apnea Protocol: Definitions, Doses, Stopping and Going Home

Definitions and physiology
  • Apnea: no breathing for 20 seconds or longer, or a shorter pause with bradycardia (<100/min), cyanosis or pallor. Events can be central, obstructive (usually pharyngeal) or mixed; most events in preterm infants are mixed.
  • Periodic breathing: regular breathing cycles of about 10–18 seconds interrupted by pauses of at least 3 seconds, with the pattern recurring for at least 2 minutes.
  • Respiratory drive and airway patency are poorly integrated below 34 weeks. Infants born at ≤25 weeks may show immature control at term and occasionally up to 44 weeks PMA.
Treatment
  • Caffeine citrate: load 20 mg/kg, then 5 mg/kg once daily IV or enterally; if apnea persists, increase to a maximum of 10 mg/kg/day. The therapeutic range is 10–20 mg/L, but levels are not routinely checked because they correlate poorly with apnea control. It acts on central and obstructive apnea, raising rate and minute ventilation with little effect on tidal volume or heart rate.
  • Who starts it: Baylor gives caffeine routinely to all infants <1250 g (for BPD prevention). In infants >28 weeks not on positive pressure, it is reasonable to wait for apnea before starting.
  • CPAP: start at 5–6 cmH₂O; above 8 is rarely needed. It works mainly by splinting the pharynx. Immature infants often need it until pharyngeal control matures at 32–34 weeks, and much longer if born at ≤27 weeks. Nurse in a servo-controlled incubator and avoid neck flexion.
  • Anaemia: red-cell transfusion may reduce apnea briefly, but there is no evidence of lasting resolution. Neither the incidence nor the response relates to the haematocrit value.
  • Reflux: there is no causal link between GER and apnea of prematurity, and anti-reflux medicines may add morbidity — do not use them to treat apnea.
Stopping caffeine and discharge
  • Trial off caffeine after 5–7 days free of clinically significant apnea, off positive pressure, or at 33–34 weeks PMA, whichever comes first. Continue cardiorespiratory monitoring for 7 days after stopping, since the caffeine half-life is about 50–100 hours. Count only spontaneous events, not feeding-related ones.
  • Most preterm infants are physiologically stable by 36–37 weeks, and about 80% are free of apnea and bradycardia by the time they are otherwise ready to go home. Very preterm infants or those with a complicated course may take until 43–44 weeks.
  • Generally no reason to delay discharge (AAP Committee on Fetus and Newborn, 2016): brief isolated bradycardias that resolve on their own, and feeding-related events that resolve when the feed is paused.
  • Expect more events in very preterm infants after elective surgery (e.g., hernia repair), eye examinations and 2-month vaccinations (rarely after the 4-month ones).
  • Home apnea monitors should not be used to send home infants without mature respiratory control, and do not prevent SIDS. Pneumograms neither predict SIDS nor identify who needs a monitor.
  • Polysomnography is not routine (no neonatal normal values, events improve with time, no mortality benefit). Consult pulmonology before ordering one, for example for severe obstructive sleep apnea or apnea persisting beyond 48 weeks PMA. An oxycardiorespirogram (HR, ECG, chest impedance and SpO₂ over 4–8 hours) is unvalidated in neonates, does not distinguish central from obstructive apnea, and is not an oxygen-titration study.

11. Precautions

Safety Cautions
  • Never attribute new/worsening apnea to prematurity without excluding secondary causes.
  • Verify caffeine dosing; watch for tachycardia/feed intolerance.
  • Address obstructive apnea (positioning/CPAP), not just central apnea.
  • Do not discharge before a safe, documented apnea-free interval off caffeine.
  • Reinforce safe sleep at discharge.

12. Escalation & Family Support

Family-Centered Communication
  • "Pauses in breathing are common in premature babies because the part of the brain controlling breathing is still maturing; a caffeine medicine helps a lot and it usually resolves with time."
  • "If breathing pauses become more frequent, we always check for other causes such as infection before assuming it's just prematurity."
  • "Before going home, we make sure your baby has had a safe stretch with no significant pauses, and we'll go through safe-sleep advice."

13. Key Pearls

High-Value Clinical Pearls
  • Significant apnea = >20 s, or shorter with bradycardia/desaturation.
  • AOP is a diagnosis of exclusion — new/worsening apnea = evaluate for sepsis/NEC/seizures.
  • Caffeine reduces apnea, BPD, and improves neurodevelopment (CAP trial) — start early.
  • Mixed apnea is commonest; add CPAP/positioning for the obstructive component.
  • Stop caffeine at mature gestation; observe an apnea-free interval before discharge.
  • Home monitors are not routinely needed.

14. Common Mistakes to Avoid

MistakeWhy it harmsBetter practice
Assuming apnea = prematurity.Misses sepsis/NEC/seizures.Exclude secondary causes first.
Delaying caffeine.More apnea/ventilation/BPD.Start early in at-risk preterm infants.
Ignoring obstructive component.Persistent events.Positioning/CPAP for obstructive/mixed.
Discharging too early.Home events/readmission.Documented apnea-free interval off caffeine.
Routine home monitors.False reassurance/burden.Reserve for selected cases.

15. Board-Style High-Yield Summary

Key Takeaways
  • AOP = immature respiratory control <34 wk; types central/obstructive/mixed (mixed commonest).
  • Significant apnea >20 s or with bradycardia/desaturation; periodic breathing is benign.
  • Always exclude secondary causes (sepsis, NEC, IVH, seizures, anemia, metabolic, GERD, drugs).
  • Caffeine is first-line (reduces apnea/BPD, improves neurodevelopment); add CPAP/positioning for obstructive/mixed.
  • Stop caffeine at mature gestation; discharge after a documented apnea-free interval.
  • Home monitoring not routine; reinforce safe sleep.

16. References

Back to Clinical Guideline Hubs